Medication Overview
Renflexis Pen (infliximab-abda) is a biosimilar to the original biologic medication infliximab, used in the treatment of various autoimmune disorders such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis. Renflexis works by inhibiting tumor necrosis factor (TNF), a substance that causes inflammation and contributes to the autoimmune response.
Who Should Consider Renflexis? Renflexis is suitable for adults and in some cases, children who:
- Have moderate to severe rheumatoid arthritis.
- Suffer from Crohn’s disease or ulcerative colitis.
- Are diagnosed with psoriatic arthritis or ankylosing spondylitis.
- Need a treatment option after other medications have not worked sufficiently.
How is Renflexis Administered? Renflexis is administered as an intravenous infusion. Infusions are typically done in a healthcare setting such as a hospital or a clinic, overseen by a healthcare professional. The first three doses are usually given at 0, 2, and 6 weeks, after which it is administered every 8 weeks.
Important Information for Renflexis Users:
- How to Use: Follow your healthcare provider’s instructions for receiving Renflexis infusions.
- Storage: Renflexis should be stored and handled by healthcare professionals.
- Side Effects: Common side effects include respiratory infections, headache, and nausea. Serious side effects can include severe infections, allergic reactions, and potential heart failure. Report any severe or unusual symptoms to your healthcare provider immediately.
- Monitoring: Regular monitoring is necessary to check for side effects and to ensure the effectiveness of the treatment. This may include blood tests and assessments for signs of infection.
Medication Warnings
- Infections: Renflexis can weaken the immune system, significantly increasing the risk of serious infections. Report any signs of infection to your healthcare provider immediately.
- Allergic Reactions: Some patients may experience severe allergic reactions during or after the infusion. Immediate medical attention is required for symptoms such as difficulty breathing, chest pain, high or low blood pressure, fever, and chills.
- Heart Failure: Patients with existing heart failure should be closely monitored as Renflexis can cause new onset or worsening of heart failure symptoms.
- Liver Injury: Rare cases of severe liver injury have been reported. Patients should report any symptoms such as jaundice, severe fatigue, or abdominal pain.
- Cancer: Long-term use of TNF blockers, including Renflexis, may increase the risk of lymphoma and other cancers.
Who Should and Shouldn’t Take Renflexis?
- Suitable Candidates:
- Individuals with certain autoimmune diseases who have not responded to standard therapies.
- Unsuitable Candidates:
- Individuals with severe, active infections.
- Patients with known hypersensitivity to infliximab products or any components of the formulation.
- Those with moderate to severe heart failure or significant liver disease.
For more detailed information and personalized advice, consult your healthcare provider.
